Polymorphic forms and co-crystals of a c-Met inhibitor

US10344041B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• David Bauer · Sudbury, US
• Matthew Bio · Boston, US
• Melanie Cooke · Arlington, US
• Katrina Woodin Copeland · Sudbury, US
• Matthew Peterson · Hopkinton, US
• Michele Potashman · Cambridge, US
• Roman Shimanovich · Watertown, US
• Helming Tan · Thousand Oaks, US

Key dates

• Filing date: Apr 30, 2018
• Grant date: Jul 9, 2019
• Expiry date: Apr 30, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.